



## Denis Migliorini

Head Neuro oncology unit, University Hospital of Geneva (HUG)

### Biography

Professor Denis Migliorini completed his internal medicine post graduate training in the University Hospitals of Strasbourg. He then moved to the University Hospitals of Geneva (HUG) where he completed his postgraduate training in medical oncology under the mentorship of Professor Pierre-Yves Dietrich.

From 2015 to 2016, he successfully completed his clinical fellowship in neuro-oncology. He holds a DAS in clinical trial management from the University of Geneva (UNIGE) and became principal investigator of several early phase trials testing various anti-tumor immunotherapy approaches, including peptide vaccines for the treatment of glioblastoma.

From 2017 to 2019, he performed a post-doctoral fellowship at the Center for Cellular Immunotherapies, University of Pennsylvania, in the laboratories of Professor Carl June and Professor Avery D. Posey. He trained in synthetic biology and T cell engineering, disciplines that enabled the development of CAR-T cell technology. In 2019, he was awarded the Swiss Bridge Foundation Prize in recognition of his work identifying neurotoxicity mechanisms of engineered cell therapies.

Returning to Switzerland in 2020, he was appointed assistant professor at the Department of Medicine of the Faculty of Medicine of the UNIGE, and holds the ISREC Chair in Brain Tumour Immunology. At the HUG, he is an attending physician, head of the Neuro-Oncology Unit and clinical coordinator of the brain tumor biobank. Professor Migliorini is a member of the Center for Translational Research in Onco-Hematology (CRTOH) steering committee